Abstract 1161P
Background
Therapeutic options for advanced melanoma patients (pts) resistant to standard treatment (Tx): immunotherapy & anti-BRAF-based targeted therapy represent a high medical need. Objective: Our aim was to evaluate the applicability of precision medicine in melanoma pts who failed standard tx based on molecular profiling (MP) of their tumors & the resulting clinical outcome.
Methods
All pts with advanced melanoma resistant to standard tx who had a MP at Gustave Roussy between April 2021 & March 2023 were included in this retrospective study. MP was performed by using Next Generation sequencing by using Foundation one CDX/liquidCDX & it was based on 3 protocols: STING (NCT04932525), MCLA-128 (NCT03321981) & STARTRK (NCT02568267) which allowed liquid & tissue biopsies studies. Molecular actionability was based on ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) classification.
Results
We performed MP for 184 pts: 174 had melanoma, 2 pts with EWSR1-ATF1 fusion & 1 with EWSR1-CREB1, which allowed a diagnosis correction to clear cell sarcoma & the initiation of the appropriate sarcoma tx, 3 BCC, 3 cSCC & 1 Merkel cell cancer. For the 174 melanoma pts, apart from the BRAF V600 mutation (50% of the pts), a putative actionable molecular orientation was found in 51.6% of the pts. The most frequent molecular alterations were: NRAS (23.2%), PTEN (12.6%), ATM (8.4%), CDKN2A (7.4%), BRAF class II (6.3%), BRAF class III (5.3%), KIT (4.2%) PIK3CA (3.2%), MAP2K1 (3.2%), NF1 (2.1%), AKT (1.1%), HRAS (1.1%), MET (1.1%), ALK (1.1%), ARID1A (1.1%), CDK4 (1.1%), CCND1 (1.1%). Molecularly matched tx was administered to 15 pts: anti-MEK (n = 11) & imatinib (n = 2). Among the 11 pts on anti-MEK, 1 partial response was seen after 9 months of tx & the remaining 10 pts rapidly progressed after 1-3 months of anti-MEK tx as for the 2 pts on imatinib. Unfortunately, no precision medicine tx was available to target the other potentially actionable mutations at the time they were needed.
Conclusions
Potentially actionable mutations can be found in more than 50% of pts with resistant melanoma. Tumor agnostic trials based on molecular alterations should be more broadly available to evaluate the potential benefit of innovative precision medicine in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1181TiP - BEPCOME-MB: Treatment of BRAFV600 mutated melanoma brain metastases with encorafenib + binimetinb + pembrolizumab with or without stereotactic radiosurgery
Presenter: Philippe Saiag
Session: Poster session 13
1188P - Landscape of Delta-like-ligand 3 (DLL3) expression across neuroendocrine neoplasms (NENs)
Presenter: Anthony Crymes
Session: Poster session 13
1189P - Mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN): Characterization of the genomic and pathological profile
Presenter: Annabella Di Mauro
Session: Poster session 13
1191P - TTF-1 expression in lung neuroendocrine tumors (NET): A gender-related biomarker
Presenter: Anna La Salvia
Session: Poster session 13
1192P - Smoking adversely affects survival of metastatic lung carcinoid patients: Analysis of a large international audit
Presenter: Sara Valpione
Session: Poster session 13
1193P - Evaluation of treatment appropriateness in patients submitted to surgery for non-functioning pancreatic neuroendocrine tumors (NF-PanNETs)
Presenter: Anna Battistella
Session: Poster session 13
1194P - Do metastatic appendiceal NETs ever develop metachronously after appendectomy or right hemicolectomy?
Presenter: Taymeyah Al-Toubah
Session: Poster session 13
1195P - Neuroendocrine Tumors (NETs): How Big Data (BD) techniques applied to Electronic Health Records (EHR) can improve our understanding of this patient population
Presenter: Jorge Hernando
Session: Poster session 13
1196P - Regional lymph node metastasis risk factors for rectal neuroendocrine tumors: A population-based study
Presenter: Dan Cao
Session: Poster session 13
1197P - Somatostatin analogs or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors
Presenter: Maria Grazia Maratta
Session: Poster session 13